Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Keown

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Seminars in Nephrology|March 1, 1990
Recombinant human erythropoietin and renal transplantation. The Canadian Erythropoietin Study GroupP A Keown
Transplantation Proceedings|February 1, 1987
The highly sensitized patient: etiology, impact, and managementP A Keown
Transplantation Proceedings|June 18, 1999
Therapeutic strategies for optimal use of novel immunosuppressantsP A Keown
Journal of Autoimmunity|April 1, 1992
Immunological monitoring in organ transplantation and autoimmune diseaseP A Keown
Transplantation Proceedings|April 1, 1988
Optimizing cyclosporine therapy: dose, levels, and monitoringP A Keown
Clinical Transplants|January 1, 1991
Annual review of transplantationP A Keown
Current Opinion in Nephrology and Hypertension|December 29, 1998
New immunosuppressive strategiesP A Keown
Transplantation Proceedings|March 26, 2004
Composite outcomes in renal transplantation using cyclosporineP A Keown
Contributions to Nephrology|January 1, 1991
Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study GroupP A Keown
Drugs|September 1, 1990
Emerging indications for the use of cyclosporin in organ transplantation and autoimmunityP A Keown
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Seminars in Nephrology|March 1, 1990
Recombinant human erythropoietin and renal transplantation. The Canadian Erythropoietin Study GroupP A Keown
Transplantation Proceedings|February 1, 1987
The highly sensitized patient: etiology, impact, and managementP A Keown
Transplantation Proceedings|June 18, 1999
Therapeutic strategies for optimal use of novel immunosuppressantsP A Keown
Journal of Autoimmunity|April 1, 1992
Immunological monitoring in organ transplantation and autoimmune diseaseP A Keown
Transplantation Proceedings|April 1, 1988
Optimizing cyclosporine therapy: dose, levels, and monitoringP A Keown
Clinical Transplants|January 1, 1991
Annual review of transplantationP A Keown
Current Opinion in Nephrology and Hypertension|December 29, 1998
New immunosuppressive strategiesP A Keown
Transplantation Proceedings|March 26, 2004
Composite outcomes in renal transplantation using cyclosporineP A Keown
Contributions to Nephrology|January 1, 1991
Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study GroupP A Keown
Drugs|September 1, 1990
Emerging indications for the use of cyclosporin in organ transplantation and autoimmunityP A Keown
Pageof 12